Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study

MT Newswires Live

03/20

Paradigm Biopharmaceuticals (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.

The site started screening patients, with the study designed to enrol 466 participants globally.

Three clinical trial sites in Moldova are expected to be activated in the coming weeks.

Its shares rose 2% in recent trading on Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2620203940"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620203940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620203940?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 09:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620203940","market":"fut","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.</p><p>The site started screening patients, with the study designed to enrol 466 participants globally.</p><p>Three clinical trial sites in Moldova are expected to be activated in the coming weeks.</p><p>Its shares rose 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-20 09:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.</p><p>The site started screening patients, with the study designed to enrol 466 participants globally.</p><p>Three clinical trial sites in Moldova are expected to be activated in the coming weeks.</p><p>Its shares rose 2% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620203940","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620203940","pubTimestamp":1773970163,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.The site started screening patients, with the study designed to enrol 466 participants globally.Three clinical trial sites in Moldova are expected to be activated in the coming weeks.Its shares rose 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","PAR.AU":"PARADIGM BIOPHARMACEUTICALS"},"translate_title":"Paradigm Biopharmaceuticals启用额外的香港站点进行全球三期膝关节骨关节炎研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.The site started screening patients, with the study designed to enrol 466 participants globally.Three clinical trial sites in Moldova are expected to be activated in the coming weeks.Its shares rose 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}